Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

[News]

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

More... (http://www.news-medical.net/news/20120919/Positive-data-from-Nektare28099s-NKTR-192-Phase-1a-study-on-acute-pain.aspx)